A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Ulcerative Colitis

I6T-MC-AMAC -

The main purpose of this study is to test the hypothesis that treatment with LY3074828 is superior to placebo in providing clinical benefit to participants with moderate to severe ulcerative colitis (UC). This study will also investigate how the body processes the drug.

Trial Summary

Age Range
18 - 75 years
Conditions the trial is for
Ulcerative Colitis
What the trial is testing?
Mirikizumab
Could I receive a Placebo?
Yes
Enrollment Goal
249
Trial Dates
Dec 9, 2015 - May 7, 2019
How long will I be in the trial?
Your participation could last up to 1 year and include 32 visits to the study center.
Trial Phase
II

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.